NEUMORA THERAPEUTICS, INC.

Analyst Reco. Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
9.17 ^USD	-1.50%		-5.17%	-46.22%

14/05	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
14/05	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	18/03	MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	08/03	MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target	12/12	MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target	10/23/10	MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating	10/23/10	MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder	10/23/10	MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target	10/23/10	MT
William Blair Starts Neumora Therapeutics With Outperform Rating	10/23/10	MT
BofA Securities Starts Neumora Therapeutics With Buy Rating	10/23/10	MT
Stifel Starts Neumora Therapeutics at Buy	10/23/10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer